Healthcare · Medical - Instruments & Supplies
Price
$148.27
Market Cap
$3.7B
Employees
15,000
Beta
0.78
Avg Volume
295,828
CEO
Vivek Jain
Business Description
ICU Medical, Inc., operating globally through its subsidiaries, is a medical technology firm that specializes in the development, manufacture, and sale of devices for both infusion therapy and critical care. Their extensive product line for infusion therapy encompasses: Needlefree Connectors: Such as the MicroClave, MicroClave Clear, and NanoClave brands. Catheter Maintenance & Disinfection: Including Neutron patency devices and SwabCap/SwabTip disinfecting caps. Hemodialysis Solutions: Like Tego connectors and ClearGuard HD antimicrobial caps. Hazardous Drug Handling: With closed system transfer devices (ChemoClave, ChemoLock) and the Diana compounding system for safe preparation. They also provide a comprehensive range of intravenous (IV) solutions, diluents, and irrigation fluids, available in diverse packaging options like flexible containers and pour bottles. These include common formulations such as sodium chloride, dextrose, balanced electrolytes, lactated ringer's, mannitol, and sterile water, alongside specialized irrigation solutions like acetic acid and glycine. In medication management, ICU Medical offers sophisticated infusion pumps, including the Plum 360 and LifeCare PCA brands. Its advanced ICU Medical MedNet software enhances medication safety by integrating smart pumps with hospital electronic health records (EHRs), asset tracking, and alarm notification platforms. Accompanying professional services are also provided. For critical care environments, their portfolio features: Hemodynamic Monitoring: Systems like Cogent 2-in-1 and CardioFlo. Cardiac Output & Oximetry: TDQ, OptiQ, and TriOx catheters. Blood Pressure Transducers: Such as Transpac. Blood Sampling Systems: Including the SafeSet closed blood sampling and conservation systems. The company distributes its products to a wide spectrum of healthcare providers, including acute care hospitals, wholesalers, ambulatory clinics, and various alternate site facilities such as outpatient clinics, home healthcare services, and long-term care centers. Established in 1984, ICU Medical maintains its headquarters in San Clemente, California.
Business History
Price Overview
Last updated: Jun 27, 2026 8:57am (just now)$148.27
-0.56 (-0.38%)
Day Range
$147.88 – $151.68
52-Week Range
$107.00 – $160.29
50-Day MA
$130.76
200-Day MA
$135.24
Volume
557,799.00
Analyst Price Targets
Low
$163.00
Consensus
$165.50
High
$170.00
(16 analysts)
Share Structure
Outstanding
24,993,585.00
Float
24,505,460.00
Free Float
98.0%
High free float
— 98.0% of shares trade freely, ~2% held by insiders/institutions
Very liquid — most shares trade freely. Low insider ownership can mean less management alignment, but makes large position sizing straightforward.
Price History (1 Year)
Revenue & Net Income Trend
The directional story — useful even when net income is negative.
Revenue
The top line — total sales before any costs or taxes are subtracted. A measure of how much business the company is doing.
Net Income
The bottom line — profit left after subtracting all expenses, interest, and taxes from revenue. Reflects accounting profitability, but includes non-cash items like depreciation, so it isn't the same as cash earned.
Operating Cash Flow
The real cash generated by the day-to-day business — selling products, paying suppliers, collecting from customers. Calculated from net income by adding back non-cash items and adjusting for timing (unpaid bills, unsold inventory). When OCF consistently lags net income, the reported profit may not be converting to real money.
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
API Direct from provider
CALC Derived from statements
P/E Ratio (Price per dollar of earnings)
APIStock Price / EPS (Diluted)
79.24
Stock Price: $148.27
EPS (Diluted): 0.03
EPS (Diluted): 0.03
P/B Ratio (Price vs net asset value)
APIStock Price / Book Value Per Share
1.66
Stock Price: $148.27
Total Equity: $2.12B
Shares: 24,904,000
Total Equity: $2.12B
Shares: 24,904,000
EV/EBITDA (Total value vs operating profit)
APIEnterprise Value / EBITDA
18.11
Market Cap: $3.71B
Total Debt: $1.34B
Cash: $307.96M
EBITDA: $326.54M
Total Debt: $1.34B
Cash: $307.96M
EBITDA: $326.54M
Enterprise Value (Takeover price (cap + debt - cash))
APIMarket Cap + Total Debt - Cash
$4.6B
Market Cap: $3.71B
Total Debt: $1.34B
Cash: $307.96M
Total Debt: $1.34B
Cash: $307.96M
Gross Margin (Revenue left after direct costs)
APIGross Profit / Revenue
36.8%
Gross Profit: $819.66M
Revenue: $2.23B
Revenue: $2.23B
Operating Margin (Revenue left after all operations)
APIOperating Income / Revenue
4.8%
Operating Income: $106.95M
Revenue: $2.23B
Revenue: $2.23B
Net Margin (Revenue left as actual profit)
APINet Income / Revenue
0.0%
Net Income: $732,000
Revenue: $2.23B
Revenue: $2.23B
ROE (Profit from shareholder equity)
APINet Income / Total Equity
2.2%
Net Income: $732,000
Total Equity: $2.12B
Total Equity: $2.12B
ROIC (Profit from all invested capital)
APINOPAT / Invested Capital
2.3%
Operating Income: $106.95M
Tax Rate: 76.9%
Equity: $2.12B
Total Debt: $1.34B
Cash: $307.96M
Tax Rate: 76.9%
Equity: $2.12B
Total Debt: $1.34B
Cash: $307.96M
Current Ratio (Can it pay short-term bills)
APICurrent Assets / Current Liabilities
2.36
Current Assets: $1.18B
Current Liabilities: $498.86M
Current Liabilities: $498.86M
Debt/Equity (Leverage — debt vs equity)
CALCTotal Debt / Total Equity
0.63
Short-Term Debt: $34.67M
Long-Term Debt: $1.31B
Total Debt: $1.34B
Total Equity: $2.12B
Long-Term Debt: $1.31B
Total Debt: $1.34B
Total Equity: $2.12B
Rev/Share (Top-line per share)
CALCRevenue / Shares Outstanding
$89.54
Revenue: $2.23B
Shares: 24,904,000
Shares: 24,904,000
Book Value/Share (Net assets per share)
CALC(Total Assets - Total Liabilities) / Shares
$85.28
Total Equity: $2.12B
Shares: 24,904,000
Shares: 24,904,000
FCF/Share (Real cash generated per share)
CALC(Operating Cash Flow + CapEx) / Shares
$3.69
Operating CF: $179.85M
CapEx: -$88.04M
Shares: 24,904,000
CapEx: -$88.04M
Shares: 24,904,000
CapEx is negative (outflow) — added to OCF to get FCF
Div Yield (Annual income from holding)
APILast Annual Dividend / Stock Price
0.0%
Last Dividend: N/A
Stock Price: $148.27
Stock Price: $148.27
Payout Ratio (Earnings paid out as dividends)
Dividends Paid / Net Income
—
Dividends Paid: N/A
Net Income: $732,000
Net Income: $732,000
Dividends paid not available in cash flow statement
Industry Benchmarks
Compares ICUI against LLM-researched typical ranges for its
industry. One research call per industry, cached indefinitely — every stock in the same industry
reuses the same baseline.
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
0
Company Classification
— What type of company is this?
1
Industry Landscape
— Where is the industry headed?
2
Company Momentum
— Where is this company trending?
3
Forward Projection
— 1Y & 2Y projected metrics (requires Layer 1 + 2)
4a
DCF Valuation
— Present value of future cash flows
4b
Earnings Power Value
— Floor value — worth with zero growth
4c
Anchored PE
— Industry PE adjusted for growth differential
4d
Reverse DCF
— What growth is the market pricing in?
4e
Revenue-Based DCF
— For growth/narrative companies (skip if mature earner)
4f
Anchored P/S
— Price-to-Sales peer comparison (skip if mature earner)
4g
Scenario Analysis
— Bull / Base / Bear (skip if mature earner)
4h
Dividend Discount Model
— For dividend/income stocks only
4i
Book Value Analysis
— For deep value / turnaround stocks only
4j
Insider Activity
— Are insiders buying or selling?
4f
Cash Flow Quality
— How trustworthy is the FCF?
4g
Debt Maturity Risk
— Can it handle its debt?
4h
Macro Environment
— Rates, market valuation, volatility
4i
Sector Intelligence
— How does this company compare within its sector?
4j
Revenue Confidence
— How reliable is the growth projection?
4k
Sensitivity Analysis
— How fragile is the fair value estimate?
4l
Sector Demand Cycle
— Is the sector in a boom, steady state, or contraction?
5
AI Investigation
— Adaptive research engine (Claude)
5b
Thesis Evaluation
— What does the market believe? (narrative/platform stocks only)
6
Valuation Synthesis
— Weighted verdict from all methods (requires Layer 4)
Income Statement (Annual)
Last updated: Jun 21, 2026 7:16pm (5d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $1.3B | $2.3B | $2.3B | $2.4B | $2.2B |
| Cost of Revenue | $824.8M | $1.6B | $1.5B | $1.6B | $1.4B |
| Gross Profit | $491.5M | $697.8M | $739.9M | $824.8M | $819.7M |
| Operating Expenses | $368.2M | $740.7M | $717.0M | $781.8M | $712.7M |
| Operating Income | $123.2M | -$42.9M | $22.8M | $43.0M | $107.0M |
| Net Income | $103.1M | -$74.3M | -$29.7M | -$117.7M | $732,000 |
| EBITDA | $223.5M | $191.5M | $253.2M | $43.0M | $326.5M |
| EPS | $4.86 | $-3.11 | $-1.23 | $-4.83 | $0.03 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
Last updated: Jun 21, 2026 7:16pm (5d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $552.8M | $208.8M | $254.2M | $308.6M | $308.0M |
| Total Current Assets | $1.0B | $1.2B | $1.2B | $1.4B | $1.2B |
| Total Assets | $1.9B | $4.5B | $4.4B | $4.2B | $4.1B |
| Current Liabilities | $200.8M | $494.6M | $481.8M | $556.2M | $498.9M |
| Long-Term Debt | $0 | $1.6B | $1.6B | $1.5B | $1.3B |
| Total Liabilities | $264.7M | $2.4B | $2.3B | $2.2B | $1.9B |
| Total Equity | $1.6B | $2.1B | $2.1B | $2.0B | $2.1B |
| Retained Earnings | $911.8M | $837.5M | $807.8M | $690.2M | $690.9M |
Cash Flow (Annual)
Last updated: Jun 21, 2026 7:16pm (5d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | $267.5M | -$62.1M | $166.2M | $204.0M | $179.8M |
| Capital Expenditure | -$81.2M | -$99.3M | -$93.7M | -$79.4M | -$88.0M |
| Free Cash Flow | $186.4M | -$161.5M | $72.5M | $124.7M | $91.8M |
| Acquisitions (net) | -$14.5M | -$1.8B | $0 | $0 | $0 |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | $0 | $0 | -$9.4M | -$12.0M | -$8.8M |
| Net Change in Cash | $156.7M | -$344.0M | $45.4M | $54.3M | $-603,000 |
Analyst Estimates (Annual)
Last updated: Jun 27, 2026 8:57am (just now)| Metric | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|
| Revenue |
$2.3B $2.2B – $2.3B
|
$2.4B $2.4B – $2.4B
|
$2.3B $2.3B – $2.3B
|
$2.4B $2.3B – $2.4B
|
| EBITDA |
$240.3M $236.1M – $243.5M
|
$250.2M $249.5M – $250.9M
|
$244.9M $242.4M – $247.5M
|
$250.7M $248.1M – $253.3M
|
| Net Income |
$231.2M $227.2M – $235.2M
|
$233.7M $173.4M – $293.9M
|
$261.5M $257.9M – $265.0M
|
$276.2M $272.4M – $279.9M
|
| EPS | — | — | — | — |
Growth Trends (YoY %)
Last updated: Jun 21, 2026 7:16pm (5d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | +73.2% | -0.9% | +5.4% | -6.4% |
| Gross Profit Growth | +42.0% | +6.0% | +11.5% | -0.6% |
| Operating Income Growth | -134.8% | +153.2% | +88.2% | +148.9% |
| Net Income Growth | -172.0% | +60.1% | -296.9% | +100.6% |
| EBITDA Growth | -14.3% | +32.2% | -83.0% | +660.0% |
Insider Trading (Recent)
Type codes
PPurchase
SSale
AAward / grant
MOption exercise
FIn-kind (tax)
CConversion
GGift
DReturn to issuer
All SEC Form 4 codes
Open market
- P Purchase
- Open-market or private purchase of shares.
- S Sale
- Open-market or private sale of shares.
Compensation (Rule 16b-3)
- A Award / grant
- Grant or award of securities (RSUs, options, etc.) under Rule 16b-3.
- D Return to issuer
- Securities disposed back to the company under Rule 16b-3.
- F In-kind (tax)
- Shares withheld or delivered to pay the option-exercise price or tax — not an open-market sale.
- I Discretionary
- Discretionary transaction under an employee plan — Rule 16b-3(f).
- M Option exercise
- Exercise or conversion of a derivative (option/RSU) into shares — exempt.
Derivatives
- C Conversion
- Conversion of a derivative security into the underlying shares.
- E Short expiration
- Expiration of a short derivative position.
- H Long expiration
- Expiration or cancellation of a long derivative position with value received.
- O OTM exercise
- Exercise of an out-of-the-money derivative.
- X ITM exercise
- Exercise of an in-the-money or at-the-money derivative.
Other exempt
- G Gift
- Bona fide gift of securities.
- L Small acquisition
- Small acquisition under Rule 16a-6.
- W Inheritance
- Acquisition or disposition by will or the laws of descent.
- Z Voting trust
- Deposit into or withdrawal from a voting trust.
Other
- J Other
- Other acquisition or disposition (explained in a Form 4 footnote).
- K Equity swap
- Transaction in an equity swap or similar instrument.
- U Tender / buyout
- Disposition via tender of shares in a change-of-control transaction.
Compensation-plan codes (A, D, F, M) are routine and rarely directional. Open-market P (buy) and S (sale) carry the most signal.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-05-22 | Woolson Daniel | S-Sale | 2,123.00 | $132.21 | $280,685 |
| 2026-05-14 | Sanzone Virginia Ruth | S-Sale | 2,447.00 | $124.08 | $303,624 |
| 2026-05-13 | KENNEDY KOLLEEN T | M-Exempt | 1,254.00 | $0.00 | $0 |
| 2026-05-13 | KENNEDY KOLLEEN T | A-Award | 1,475.00 | $0.00 | $0 |
| 2026-05-13 | KENNEDY KOLLEEN T | M-Exempt | 1,254.00 | $0.00 | $0 |
| 2026-05-13 | Hernandez Laurie | M-Exempt | 1,254.00 | $0.00 | $0 |
| 2026-05-13 | Hernandez Laurie | A-Award | 1,475.00 | $0.00 | $0 |
| 2026-05-13 | Hernandez Laurie | M-Exempt | 1,254.00 | $0.00 | $0 |
| 2026-05-13 | FINNEY ELISHA W | M-Exempt | 1,254.00 | $0.00 | $0 |
| 2026-05-13 | FINNEY ELISHA W | A-Award | 1,475.00 | $0.00 | $0 |
| 2026-05-13 | FINNEY ELISHA W | M-Exempt | 1,254.00 | $0.00 | $0 |
| 2026-05-13 | Abbey Donald | M-Exempt | 1,254.00 | $0.00 | $0 |
| 2026-05-13 | Abbey Donald | A-Award | 1,475.00 | $0.00 | $0 |
| 2026-05-13 | Abbey Donald | M-Exempt | 1,254.00 | $0.00 | $0 |
| 2026-05-13 | Hoffmeister David F | M-Exempt | 1,254.00 | $0.00 | $0 |
| 2026-05-13 | Hoffmeister David F | A-Award | 1,475.00 | $0.00 | $0 |
| 2026-05-13 | Hoffmeister David F | M-Exempt | 1,254.00 | $0.00 | $0 |
| 2026-05-12 | Greenberg David C. | M-Exempt | 2,424.00 | $101.06 | $244,969 |
| 2026-05-13 | Greenberg David C. | M-Exempt | 1,254.00 | $0.00 | $0 |
| 2026-05-12 | Greenberg David C. | S-Sale | 2,424.00 | $122.91 | $297,934 |
Narrative Economics
The story the market is telling about this stock — the intangible X-factor
(founder mythology, cult dynamics, TAM-of-imagination) that moves price beyond
what cash flows alone explain. After Shiller, Narrative Economics.
No narrative profile yet for ICUI — it's generated by the pipeline (
market-narrative step).
No community reviews yet for ICUI.
Be the first — hit How to Contribute, have any AI review this page, and paste its take back here.
My Notes
personal — only you see this
Sign in to save personal notes and rate your interest in this stock.
Data via Financial Modeling Prep · Cached for performance · fmp
v1.1.352 · d1100787 · 2026-06-26 11:39:30